Two dates are reshaping cervical cancer screening. In 2026, the FDA cleared at-home HPV self-collection, making it possible to screen without a clinic visit or pelvic exam. In 2027, federal coverage requirements take effect, expanding access to at-home HPV screening for members nationwide. Together they turn at-home self-collection from an emerging option into an expected standard of care.
When coverage requirements land, plans that have never run an at-home program will be starting from zero: sourcing kits, standing up engagement, contracting a lab, and building reporting, all at once, under a deadline. Plans that have already run a program will simply scale one that works. The gap between those two positions is measured in closed CCS gaps and Star performance.
The practical move is to run at-home HPV self-collection now, for measurement year 2026, rather than treating 2027 as the starting line. That means choosing a partner who can be live quickly, close the CCS gap with documentation that holds up under audit, and reach the underserved members who drive the widest gaps. Launching in weeks, not months, is realistic with a fully integrated partner.
SNT Biotech operates a fully integrated at-home HPV self-collection solution for health plans, in partnership with Waters Corporation, processed in our own accredited lab. We are onboarding national and regional plans now, so the program is proven and running before the coverage shift, not scrambling to meet it. The plans that act early will spend 2027 ahead, not behind.
Onboard your plan now and be live for measurement year 2026.